Characteristics of Those Patients Who Developed a Second Cancer After HD
| Patient . | Sex/Age (yr) . | Histology . | Stage . | Bulk . | RT . | DI (6 cycles) . | Clinical Response . | Relapse . | Time4-150 (mo) . | Present Status . | Second Cancer . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M.C. | M/62 | MC | III B | + | − | 0.76 | CR | − | 0 | Deceased | SCLC |
| M.G. | M/71 | LD | IV B | − | − | 0.68 | CR | − | 25 | Alive | Sigmoid carcinoma |
| F.A. | M/44 | MC | IIIS A | − | − | 0.69 | CR | + | 50 | Deceased | RAEB |
| S.A. | M/61 | LD | II B | + | + | 0.67 | CR | − | 55 | Deceased | SCLC |
| G.P. | M/43 | NS | IV A | − | − | 0.68 | CR | − | 55 | Alive | RAEB |
| F.P. | M/58 | NS | IV A | − | − | 0.77 | CR | − | 60 | Alive | Colon carcinoma |
| G.M. | F/29 | MC | III A | + | + | 0.86 | CR | + | 62 | Alive | Frontal bone eosinophilic granuloma |
| S.F. | F/27 | NS | III A | − | − | 0.90 | CR | − | 77 | Alive | RAEB |
| Patient . | Sex/Age (yr) . | Histology . | Stage . | Bulk . | RT . | DI (6 cycles) . | Clinical Response . | Relapse . | Time4-150 (mo) . | Present Status . | Second Cancer . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M.C. | M/62 | MC | III B | + | − | 0.76 | CR | − | 0 | Deceased | SCLC |
| M.G. | M/71 | LD | IV B | − | − | 0.68 | CR | − | 25 | Alive | Sigmoid carcinoma |
| F.A. | M/44 | MC | IIIS A | − | − | 0.69 | CR | + | 50 | Deceased | RAEB |
| S.A. | M/61 | LD | II B | + | + | 0.67 | CR | − | 55 | Deceased | SCLC |
| G.P. | M/43 | NS | IV A | − | − | 0.68 | CR | − | 55 | Alive | RAEB |
| F.P. | M/58 | NS | IV A | − | − | 0.77 | CR | − | 60 | Alive | Colon carcinoma |
| G.M. | F/29 | MC | III A | + | + | 0.86 | CR | + | 62 | Alive | Frontal bone eosinophilic granuloma |
| S.F. | F/27 | NS | III A | − | − | 0.90 | CR | − | 77 | Alive | RAEB |
The table also reports the patient whose second tumor, diagnosed at the end of therapy for HD, should properly be considered a synchronous cancer (first line).
Abbreviations: DI, dose intensity; SCLC, small-cell lung cancer; RAEB, refractory anemia with excess of blasts.
Time from the end of therapy to the diagnosis of second cancer.